Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis UC Irvine UCLA
Dates
study started
completion around
Principal Investigator
by S. Samuel Weigt, MD (ucla)
Headshot of S. Samuel Weigt
S. Samuel Weigt

Description

Summary

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.

Official Title

A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Details

Keywords

Progressive Pulmonary Fibrosis, Interstitial Lung Disease, Treprostinil, PPF, ILD, Lung Diseases, Pulmonary Fibrosis, Interstitial Lung Diseases, Fibrosis, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer

Eligibility

Locations

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
United Therapeutics
ID
NCT05943535
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 698 study participants
Last Updated